SCHEMBL1011633

SCHEMBL1011633

O=C1CN(Cc2ccccc2)C(=O)N1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.69
CRBN Q96SW2 1/20 0.69
EPHX2 P34913 1/20 0.68
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
GAA P10253 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
F2 P00734 1/20 0.45
PLG P00747 1/20 0.45
ELANE P08246 1/20 0.45
CTSG P08311 1/20 0.45
CMA1 P23946 1/20 0.45
CTRC Q99895 1/20 0.45
POLB P06746 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9850086 1.00 DDB1 (0.69) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL9850110 0.98 DDB1 (0.67) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL2001787 0.90 ENPP2 (0.57) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL10649531 0.84 EPHX2 (0.62) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL9164640 0.83 EPHX2 (0.49) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL6827489 0.81 DDB1 (1.00) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL22144492 0.81 EPHX2 (0.47) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL28757730 0.81 EPHX2 (0.47) DDB1CRBNEPHX2GAAHDAC2
SCHEMBL20189142 0.81 EPHX2 (0.47) DDB1CRBNEPHX2KMT2AMEN1
SCHEMBL8009140 0.81 EPHX2 (0.47) DDB1CRBNEPHX2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116514646-A Preparation method of phenylpyruvic acid 浙江昂利泰制药有限公司 2023-08-01 CN claimed
CN-114315619-B Synthesis method of dimethoxy dopa 山东泓瑞医药科技股份公司 2023-03-24 CN claimed
CN-114315619-A Synthetic method of 3- (3, 4-dimethoxyphenyl) -L-alanine 山东泓瑞医药科技股份公司 2022-04-12 CN claimed
EP-3716966-A2 ALPHA KETO ACID COMPOSITIONS FOR TREATING HYPO-ALBUMINEMIA Hull, Edgar, L., Jr. (US) 2020-10-07 EP claimed
US-20200281881-A1 Alpha Keto Acid Compositions for Treating Hypo-Albuminemia Hull, Jr., Edgar L. (US) 2020-09-10 US claimed
US-20080241896-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE HYDROXYMETHYL-SUBSTITUTED PHENYLALANINE AJINOMOTO CO., INC. (JP) 2008-10-02 US claimed
CN-100407923-C Sterilization disinfectant and application thereof NANJING UNIVERSITY OF TECHNOLOGY (CN) 2008-08-06 CN claimed
EP-1867730-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE HYDROXYMETHYL -SUBSTITUTED PHENYLALANINE Ajinomoto Co., Inc. (JP) 2007-12-19 EP claimed
EP-1827434-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER Amgen Inc. (US) 2007-09-05 EP claimed
CN-1788564-A Sterilization disinfectant and application thereof NANJING UNIVERSITY OF TECHNOLOGY (CN) 2006-06-21 CN claimed
WO-2006060318-A2 QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER AMGEN INC. (US) 2006-06-08 WO claimed
EP-0159866-B1 PROCESS FOR PRODUCTION OF L-AMINO ACIDS DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1991-04-03 EP claimed
JP-6100543-A None JP disclosed
EP-4686757-A1 INHIBITORS OF EXPRESSION AND/OR FUNCTION e-therapeutics PLC (GB) 2026-02-04 EP disclosed
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME SANOFI US SERVICES INC. (US) 2025-07-17 US disclosed
EP-4532487-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME Sanofi US Services Inc. (US) 2025-04-09 EP disclosed
US-4293563-A ANTIASTHMATICS LILLY INDUSTRIES LIMITED (GB) 1981-10-06 US disclosed
US-4241073-A ASTHMA LILLY INDUSTRIES LIMITED (GB) 1980-12-23 US disclosed
EP-0005647-A1 Hydantoin compounds, their preparation and pharmaceutical formulations containing them Lilly Industries Limited (GB) 1979-11-28 EP disclosed
US-4016037-A FERMENTING A HYDANTOIN COMPOUND WITH FLAVOBACTERIUM AMINOGENES OR ITS ENZYMES AJINOMOTO CO., INC. (JA) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200281881-A1 Alpha Keto Acid Compositions for Treating Hypo-Albuminemia ALB, AADAT, BCAT2 DDB1 4731/4885CRBN 2096/4885EPHX2 3821/4885
US-20250228865-A1 COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME UPF1, NUDT21, RNGTT DDB1 773/4885CRBN 1442/4885EPHX2 2855/4885
US-20080241896-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE HYDROXYMETHYL-SUBSTITUTED PHENYLALANINE PAH, HPD, DAO DDB1 3013/4885CRBN 3314/4885EPHX2 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.